Assessing antibiotic therapy effectiveness against the major bacterial pathogens in a hospital using an integrated index

Future Microbiology

Volumn 12, Issue 10, 2017, Pages 853-866

  Chen, Yong ^a   Song, Boqiang ^b,c   Shan, Xue ^d   Qin, Yanhong ^a   Wang, Liang ^d   Wang, Hongyuan ^d   Lu, Zhongyi ^a   Liu, Lin ^a   Yin, Danping ^e   Han, Xuelin ^a   Zhao, Jingya ^a   Tian, Shuguang ^a   Chen, Fangyan ^a   Su, Xueting ^a   Huang, Liuyu ^f   Li, Qi ^b   Grundmann, Hajo ^g   Zhang, Hong ^a   Han, Li ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b PEKING UNIVERSITY   (China)

^c Beijing Advanced Innovation Center for Future Internet Technology   (China)

^d PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^e JINAN MILITARY GENERAL HOSPITAL   (China)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

antimicrobial resistance; drug resistance index; inadequate antibiotic treatment; infection control; nosocomial infection

Indexed keywords

ANTIINFECTIVE AGENT; PRESCRIPTION DRUG;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; BACTERIUM; CHINA; CROSS INFECTION; DRUG EFFECTS; ESCHERICHIA COLI; HOSPITAL; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TEST; PATHOGENICITY; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ACINETOBACTER; ANTI-BACTERIAL AGENTS; BACTERIA; BEIJING; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; HOSPITALS; HUMANS; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; PRESCRIPTION DRUGS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 85026913893     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb-2017-0025     Document Type: Article

References (22)

1. World Health Organization. The evolving threat of antimicrobial resistance-introduction. In: The Evolving Threat of Antimicrobial Resistance: Options for Action. WHO Press, Geneva, Switzerland, 1-11 (2012).
2. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 36(11), 1433-1437 (2003).
3. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev. Infect. Dis. 9(6), 1065-1078 (1987).
4. Laxminarayan R, Duse A, Wattal C et al. Antibiotic resistance-The need for global solutions. Lancet Infect. Dis. 13(12), 1057-1098 (2013).
5. Xiao YH, Giske CG, Wei ZQ, Shen P, Heddini A, Li LJ. Epidemiology and characteristics of antimicrobial resistance in China. Drug Resist. Updat. 14(4-5), 236-250 (2011).
6. Sweidan M, Zhang Y, Harvey K, Yang Y, Shen X, Yao K. Proceedings of the 2nd National Workshop on Rational Use of Antibiotics in China. Beijing, China, 28-30 November 2005.
7. Xiao Y, Zhang J, Zheng B, Zhao L, Li S, Li L. Changes in Chinese policies to promote the rational use of antibiotics. PLoS Med. 10(11), e1001556 (2013).
8. Laxminarayan R, Klugman KP. Communicating trends in resistance using a drug resistance index. BMJ Open 1(2), e000135 (2011).
9. Ciccolini M, Spoorenberg V, Geerlings SE, Prins JM, Grundmann H. Using an index-based approach to assess the population-level appropriateness of empirical antibiotic therapy. J. Antimicrob. Chemother. 70(1), 286-293 (2015).
10. van Buul LW, Van Der Steen JT, Achterberg WP et al. Effect of tailored antibiotic stewardship programmes on the appropriateness of antibiotic prescribing in nursing homes. J. Antimicrob. Chemother. 70(7), 2153-2162 (2015).
11. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteen Informational Supplement M100-S18. CLSI, Wayne, PA, USA (2008).
12. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Sixteenth Informational Supplement M100-S20. CLSI, Wayne, PA, USA (2010).
13. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Third Informational Supplement M100-S23. CLSI, Wayne, PA, USA (2013).
14. Dellit TH, Owens RC et al., Mcgowan JE Jr Infectious diseases society of America and the society for healthcare epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44(2), 159-177 (2007).
15. Lin H, Dyar OJ, Rosales-Klintz S et al. Trends and patterns of antibiotic consumption in Shanghai municipality, China: A 6-year surveillance with sales records, 2009-2014. J. Antimicrob. Chemother. 71(6), 1723-1729 (2016).
16. Ren N, Zhou P, Wen X et al. Point prevalence survey of antimicrobial use in Chinese hospitals in 2012. Am. J. Infect. Control 44(3), 332-339 (2016).
17. Hu FP, Guo Y, Zhu DM et al. Resistance trends among clinical isolates in China reported from CHINET surveillance of bacterial resistance, 2005-2014. Clin. Microbiol. Infect. 22(Suppl. 1), S9-S14 (2016).
18. Grundmann H, Glasner C, Albiger B et al. Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): A prospective, multinational study. Lancet Infect. Dis. 17(2), 153-163 (2017).
19. Sader HS, Farrell DJ, Flamm RK, Jones RN. Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalised with pneumonia in US and European hospitals: results from the SENTRY Antimicrobial Surveillance Program, 2009-2012. Int. J. Antimicrob. Agents 43(4), 328-334 (2014).
20. Liu JY, Wu YH, Cai M, Zhou CL. Point-prevalence survey of healthcare-Associated infections in Beijing, China: A survey and analysis in 2014. J. Hosp. Infect. 93(3), 271-279 (2016).
21. Xie DS, Fu XY, Wang HF et al. Annual point-prevalence of healthcare-Associated infection surveys in a university hospital in China, 2007-2011. J. Infect. Public Health 6(6), 416-422 (2013).
22. Evans RS. Electronic health records: Then, now, and in the future. Yearb. Med. Inform. 25(Suppl. 1), S48-S61 (2016).